MEG
ALNY icon

Millstone Evans Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Millstone Evans Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.01K Sell
10
-30
-75% -$9.05K ﹤0.01% 742
2026
Q1 		$13.2K Hold
40
– – 0.01% 538
2025
Q4 		$15.9K Hold
40
– – 0.01% 493
2025
Q3 		$18.2K Buy
+40
New +$16.3K 0.01% 464

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Millstone Evans Group's ALNY Position: Q2 2026 in Review

Millstone Evans Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 75% in Q2 2026, selling an estimated $9.05K and leaving 10 shares worth $3.01K. The position accounts for ﹤0.01% of the portfolio, ranked #742.

Millstone Evans Group first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $18.2K in Q3 2025. 594 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Millstone Evans Group held 10 shares of Alnylam Pharmaceuticals worth $3.01K as of Q2 2026.
  • Millstone Evans Group sold 30 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $9.05K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Millstone Evans Group's portfolio in Q2 2026, its #742 holding.
  • Millstone Evans Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Millstone Evans Group's Alnylam Pharmaceuticals position peaked at $18.2K in Q3 2025.
  • 594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.